The m6A reader YTHDF2 is a negative regulator for dendrite development and maintenance of retinal ganglion cells

  1. Fugui Niu
  2. Peng Han
  3. Jian Zhang
  4. Yuanchu She
  5. Lixin Yang
  6. Jun Yu
  7. Mengru Zhuang
  8. Kezhen Tang
  9. Yuwei Shi
  10. Baisheng Yang
  11. Chunqiao Liu
  12. Bo Peng  Is a corresponding author
  13. Sheng-J Ji  Is a corresponding author
  1. School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, China
  2. SUSTech-HIT Joint Graduate Program, Southern University of Science and Technology, China
  3. Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, China
  4. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, China
  5. Department of Neurosurgery, Jinshan Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, China
  6. Co-Innovation Center of Neuroregeneration, Nantong University, China

Abstract

The precise control of growth and maintenance of the retinal ganglion cell (RGC) dendrite arborization is critical for normal visual functions in mammals. However, the underlying mechanisms remain elusive. Here, we find that the N6-methyladenosine (m6A) reader YTHDF2 is highly expressed in the mouse RGCs. Conditional knockout (cKO) of Ythdf2 in the retina leads to increased RGC dendrite branching, resulting in more synapses in the inner plexiform layer. Interestingly, the Ythdf2 cKO mice show improved visual acuity compared with control mice. We further demonstrate that Ythdf2 cKO in the retina protects RGCs from dendrite degeneration caused by the experimental acute glaucoma model. We identify the m6A-modified YTHDF2 target transcripts which mediate these effects. This study reveals mechanisms by which YTHDF2 restricts RGC dendrite development and maintenance. YTHDF2 and its target mRNAs might be valuable in developing new treatment approaches for glaucomatous eyes.

Editor's evaluation

In this study, you propose a role for the m6A reader YTHDF2 in regulating the dendritic arbor size of retinal ganglion cells (RGCs). You show that retina-specific loss of Ythdf2 leads to the expansion of RGC dendritic arbors in the horizontal plane and a widening of the inner plexiform layer (IPL), with Ythdf2 conditional knockouts showing a modest increase in visual acuity in an optomotor assay. You point to a number of factors downstream of YTHDF2 not previously known to be involved in retinal dendritic development, and propose a role for YTHDF2 in a glaucoma model, in which loss of YTHDF2 is shown to prevent RGC loss. This study presents a careful phenotypic analysis of manipulation of YTHDF2 and provides a foundation for studies on how YTHDF2-mediated mechanisms are integrated into programs of dendritic development and RGC survival.

https://doi.org/10.7554/eLife.75827.sa0

Introduction

The mammalian retina is an ideal model system to study neuronal development and neural circuit formation. The retinal ganglion cells (RGCs) are the final and only output neurons in the vertebrate retina and their dendrites collect the electrical information concerning the visual signal from all other cells preceding them. One of the major focuses of research in the retina is to understand how RGC dendrite arborization arises during development (Prigge and Kay, 2018). Existing evidences supported that homotypic repulsion controls retinal dendrite patterning (Lefebvre et al., 2015). However, in mice which had most RGCs genetically eliminated, the dendrite size and shape of remaining RGCs appeared relatively normal (Lin et al., 2004). Thus, the fact that the dendrites of remaining RGCs did not expand to neighboring areas by the remaining RGCs supports the existence of the intrinsic limit for RGC dendrite patterning, which cooperates with the homotypic repulsion to determine the dendrite size of RGCs (Lefebvre et al., 2015). However, such intrinsic limiting mechanisms remain elusive.

Glaucoma is one of the leading causes for blindness. The major risk factors for glaucoma include increased intraocular tension. Studies have shown that glaucoma causes pathological changes in RGC dendrites before axon degeneration and soma loss were detected in different model animals (Weber et al., 1998; Shou et al., 2003; Morgan et al., 2006). Thus, elucidation of mechanisms governing RGC dendrite arbor maintenance bears clinical significance.

N6-methyladenosine (m6A) is the most widely distributed and extensively studied internal modification in mRNA (Dominissini et al., 2012; Meyer et al., 2012; Nachtergaele and He, 2018). m6A modification has been shown to regulate brain development and functions in the nervous system (Livneh et al., 2020; Yu et al., 2021a). By effectors, most of these studies have focused on its demethylases (‘m6A erasers’) and methyltransferases (‘m6A writers’). Since the fate of m6A-modified transcripts is decoded by the m6A-binding proteins (‘m6A readers’), how the readers mediate these functions and what are their neural target mRNAs remain to be elucidated. In addition, more precisely controlled spatial-temporal ablation of the m6A readers instead of null knockout is required to elucidate their functions and mechanisms in nervous system.

In this study, we identified an m6A-dependent intrinsic limiting mechanism for RGC dendrite arborization and maintenance. Conditional knockout (cKO) of the m6A reader YTHDF2 in the developing mouse retina increases RGC dendrite branching and improves visual acuity. YTHDF2 also mediates acute ocular hypertension (AOH)-induced RGC degeneration, the experiment model for glaucoma, and Ythdf2 cKO in the retina alleviates AOH-induced RGC dendrite shrinking and neuronal loss. The regulation of RGC dendrite development and maintenance by YTHDF2 is mediated by two distinct groups of m6A-modified target mRNAs which encode proteins that promote dendrite arborization during development and maintain dendrite tree during injury, respectively. Therefore, our study reveals mechanisms by which YTHDF2 restricts RGC dendrite development and maintenance, which sheds light on developing new treatment approaches for glaucomatous eyes.

Results

Knockdown of YTHDF2 leads to a robust increase of RGC dendrite branching

To examine whether m6A modification and its reader proteins play a role in the dendrite development, we utilized the retina as the model system. We first checked their expression patterns in the developing mouse retina. Immunostaining with a widely used m6A antibody demonstrated that RGCs had high m6A modification levels (Figure 1—figure supplement 1A). Consistent with the m6A distribution, the m6A reader YTHDF2 is highly expressed in RGCs (Figure 1A; Figure 1—figure supplement 1B). Conversely, the expression of YTHDF2 in other layers and cells of the retina is much lower or absent (Figure 1A; Figure 1—figure supplement 1B-D). Another two m6A readers YTHDF1 and YTHDF3 show similar expression patterns (Figure 1—figure supplement 1E, F). The strong expression of YTHDFs and high level of m6A modification in RGCs suggest that the m6A reader YTHDFs might play roles in RGC development. We dissected and dissociated the retinal cells and cultured in vitro. We generated lentiviral shRNAs against YTHDFs, which showed similarly efficient knockdown (KD) of YTHDFs in RGC cultures in vitro (Figure 1B; Figure 1—figure supplement 1G,H). In these YTHDF-deficient RGC cultures, the first and most obvious phenotype that we observed is the robust increase of dendrite branching of cultured RGCs treated by shYthdf2 (Figure 1C and D; Figure 1—figure supplement 1I,J). In contrast, the dendrite branching of RGCs with YTHDF1 KD using shYthdf1 was not significantly different from control shRNA (Figure 1—figure supplement 1K), while YTHDF3 KD using shYthdf3 caused a slight (statistically significant in several Sholl radii) decrease of RGC dendrite branching compared with control shRNA (Figure 1—figure supplement 1L). These results suggest that the m6A reader YTHDF2 might play an important role in controlling dendrite branching of RGCs.

Figure 1 with 1 supplement see all
Knockdown (KD) of YTHDF2 leads to a robust increase of retinal ganglion cell (RGC) dendrite branching.

(A) Representative confocal images showing high expression of YTHDF2 in RGCs (marked by RBPMS) in P0 retina. Note that all RGCs marked by the pan-RGC marker RBPMS express YTHDF2 while all YTHDF2-expressing cells are RBPMS+ RGCs. GCL, ganglion cell layer. Scale bars: 20 μm. (B) Western blotting (WB) confirming efficient KD of YTHDF2 in cultured RGCs using shYthdf2. Data of WB quantification are mean ± SEM and are represented as dot plots: ***p = 0.00012 (n = 3 replicates); by unpaired Student’s t test. (C) Examination of RGC dendrite development after YTHDF2 KD. As shown, significantly increased branching of dendrites marked by MAP2 immunofluorescence was observed in cultured RGCs marked by Brn3a. Dendrite traces were drawn for the corresponding RGCs. Scale bar: 10 μm. (D) Quantification of dendrite branching (C) using Sholl analysis. As shown, numbers of interactions are significantly greater in shYthdf2 groups (n = 68 RGCs) than shCtrl groups (n = 72 RGCs) in Sholl radii between 10 and 30 μm. Data are mean ± SEM. ****p = 4.32E-05 (10 μm), ***p = 0.00038 (15 μm), ****p = 2.85E-05 (20 μm), ***p = 0.00084 (25 μm), *p = 0.020 (30 μm), by unpaired Student’s t test.

Figure 1—source data 1

Source data for Figure 1B.

(A) Western blotting (WB) of anti-YTHDF2 after knockdown (KD) of YTHDF2. (B) WB of anti-β-actin after KD of YTHDF2.

https://cdn.elifesciences.org/articles/75827/elife-75827-fig1-data1-v2.zip
Figure 1—source data 2

Source data for Figure 1B.

Original file of the full raw unedited blot of anti-YTHDF2 after knockdown (KD) of YTHDF2.

https://cdn.elifesciences.org/articles/75827/elife-75827-fig1-data2-v2.zip
Figure 1—source data 3

Source data for Figure 1B.

Original file of the full raw unedited blot of anti-β-actin after knockdown (KD) of YTHDF2.

https://cdn.elifesciences.org/articles/75827/elife-75827-fig1-data3-v2.zip

cKO of Ythdf2 in the retina increases RGC dendrite branching in vivo without disturbing sublaminar targeting

To further explore whether YTHDF2 physiologically regulates RGC dendrite branching in vivo, we generated Ythdf2 cKO mouse (Figure 2A). We used the Six3-cre mouse line (Furuta et al., 2000), which has been widely used in the field to generate retina-specific knockouts (Lefebvre et al., 2012; Riccomagno et al., 2014; Sapkota et al., 2014; Krishnaswamy et al., 2015). YTHDF2 expression is efficiently eliminated in the Ythdf2 cKO retina compared with their littermate controls at E12.5 (Figure 2—figure supplement 1A) and E15.5 (Figure 2B). Retina progenitors, amacrine cells, bipolar cells, photoreceptors, horizontal cells, Müller glia, or astrocytes were not affected in Ythdf2 cKO retina (Figure 2—figure supplement 1B-K; Figure 2—figure supplement 2A-D), suggesting that YTHDF2 is not involved in the generation or development of these cells. This is in line with the low or no YTHDF2 expression in these cells. The RGC number or density was not affected in the Ythdf2 cKO retina (Figure 2C and D), demonstrating that Ythdf2 knockout does not disturb RGC neurogenesis. We then cultured RGCs from the Ythdf2 cKO retina. The dendrite branching of Ythdf2 cKO RGCs was significantly increased compared with littermate controls (Figure 2E and F). RGCs include over 40 subtypes (Sanes and Masland, 2015; Baden et al., 2016). We thus examined the RGC dendrite branching within different subtypes. One of the RGC subgroups responds preferentially to movement in particular directions and is named the ON-OFF directionally selective RGCs (ooDSGCs). Expression of CART (cocaine- and amphetamine-regulated transcript), a neuropeptide, distinguishes ooDSGCs from other RGCs (Kay et al., 2011a). The dendrite branching of ooDSGCs marked by CART/Brn3a co-staining in Ythdf2 cKO retinal cultures also increased compared with control (Figure 2G and H). These data further confirm that the m6A reader YTHDF2 regulates dendrite branching of RGCs.

Figure 2 with 2 supplements see all
Dendrite branching is dramatically increased in cultured retinal ganglion cells (RGCs) from Ythdf2 conditional knockout (cKO).

(A) Schematic drawings of the genetic deletion strategy for Ythdf2. Exon 4 which contains YTH domain-coding sequence is deleted after Cre-mediated recombination. (B) Depletion of YTHDF2 protein in retina of Six3-cre+/-;Ythdf2fl/fl cKO mice. Anti-YTHDF2 immunostaining of E15.5 retina vertical sections confirmed cKO of YTHDF2 protein, compared with Ythdf2fl/fl littermate controls. Scale bar: 20 μm. (C, D) RGC neurogenesis not affected in the Ythdf2 cKO retina. Wholemount immunostaining using a Brn3a antibody was carried out in P20 retina (C). Numbers of Brn3a+ RGC per 10,000 μm2 of retina were quantified and showed no difference between the Ythdf2 cKO and their littermate controls (D). n = 12 confocal fields for each genotype. Data are represented as box and whisker plots: ns, not significant (p = 0.79); by unpaired Student’s t test. Scale bar: 25 μm. (E) Examination of RGC dendrite development in Ythdf2 cKO RGCs. As shown, knockout of YTHDF2 was confirmed by YTHDF2 IF (green). Significantly increased branching of dendrites marked by MAP2 IF (red) was observed in cultured RGCs from the Ythdf2 cKO retina compared with their littermate controls. Dendrite traces were drawn for the corresponding RGCs. Scale bar: 10 μm. (F) Quantification of RGC dendrite branching (E) using Sholl analysis. Data are mean ± SEM. Numbers of interactions are significantly greater in Six3-cre+/-,Ythdf2fl/fl groups (n = 68 RGCs) than Ythdf2fl/fl groups (n = 42 RGCs) in Sholl radii between 10 and 30 μm: ***p = 0.00030 (10 μm), ****p = 1.19E-05 (15 μm), ***p = 0.00018 (20 μm), *p = 0.021 (25 μm), **p = 0.0022 (30 μm), by unpaired Student’s t test. (G) Examination of CART+ (cocaine- and amphetamine-regulated transcript) RGC dendrite development in Ythdf2 cKO RGCs. Cultured CART+ RGCs from the Ythdf2 cKO retina have significantly increased branching of dendrites marked by MAP2 IF (red) compared with their littermate controls. Dendrite traces were drawn for the corresponding RGCs. Scale bar: 10 μm. (H) Quantification of CART+ RGC dendrite branching (G) using Sholl analysis. Data are mean ± SEM. Numbers of interactions are significantly greater in Six3-cre+/-,Ythdf2fl/fl groups (n = 77 RGCs) than Ythdf2fl/fl groups (n = 90 RGCs) in Sholl radii between 10 and 30 μm: ****p = 3.17E-05 (10 μm), ****p = 6.50E-11 (15 μm), ****p = 5.14E-12 (20 μm), ****p = 5.00E-07 (25 μm), ***p = 0.00020 (30 μm), by unpaired Student’s t test.

Next, we wanted to confirm this phenotype in vivo by checking specific RGC subtypes. Intravitreal injection of an AAV reporter expressing ZsGreen visualized the dendrite morphology of ooDSGCs marked by CART immunostaining (Figure 3A). ooDSGCs showed dramatically increased dendrite branching in Ythdf2 cKO retina compared with control retina by Sholl analysis (Figure 3A and B). The intrinsically photosensitive RGCs (ipRGCs) are unique and melanopsin-expressing cells, which exhibit an intrinsic sensitivity to light (Hattar et al., 2002). We analyzed the morphology of ipRGCs visualized by wholemount immunostaining of melanopsin and found that the dendrite branching of ipRGCs was significantly increased in the Ythdf2 cKO retina (Figure 3C and D; Figure 3—figure supplement 1A-E). A similar trend was observed in the SMI-32+αRGCs (Figure 3E and F). These results strongly indicate that the m6A reader YTHDF2 negatively regulates RGC dendrite branching in vivo and Ythdf2 cKO promotes RGC dendrite arborization.

Figure 3 with 1 supplement see all
Dendrite branching of specific retinal ganglion cell (RGC) subtypes increases in Ythdf2 conditional knockout (cKO) in vivo.

(A) Co-labeling of ON-OFF directionally selective RGCs (ooDSGCs) by AAV-ZsGreen and CART (cocaine- and amphetamine-regulated transcript) IF in vivo. Intravitreal injection of AAV-expressing ZsGreen reporter was performed at P17 and retinas were collected at P27. The white arrowheads indicate ooDSGCs co-labeled by ZsGreen and CART IF, which show dramatically increased dendrite branching in Ythdf2 cKO compared with control. Dendrite traces were drawn for the corresponding RGCs shown. Scale bar: 20 μm. (B) Quantification of dendrite branching of ZsGreen+/CART+ ooDSGCs (A) using Sholl analysis. Data are mean ± SEM. Numbers of interactions are significantly greater in Six3-cre+/-,Ythdf2fl/fl groups (n = 15 RGCs) than Ythdf2fl/fl groups (n = 18 RGCs) in Sholl radii between 50 and 120 μm: **p = 0.0041 (50 μm), **p = 0.0059 (60 μm), ***p = 0.00036 (70 μm), **p = 0.0058 (80 μm), **p = 0.0018 (90 μm), **p = 0.0064 (100 μm), **p = 0.0045 (110 μm), *p = 0.040 (120 μm), by unpaired Student’s t test. (C) Dendrites of intrinsically photosensitive RGCs (ipRGCs) visualized by wholemount immunostaining of P20 retina using a melanopsin antibody in vivo. Dendrite traces were drawn for the corresponding RGCs shown. Scale bar: 50 μm. (D) Quantification of dendrite branching of melanopsin+ ipRGCs (C) using Sholl analysis. Data are mean ± SEM. Numbers of interactions are significantly greater in Six3-cre+/-,Ythdf2fl/fl groups (n = 18 RGCs) than Ythdf2fl/fl groups (n = 21 RGCs) in Sholl radii between 20 and 100 μm: **p = 0.0083 (20 μm), *p = 0.018 (40 μm), ***p = 0.00068 (50 μm), ***p = 0.00027 (60 μm), *p = 0.048 (70 μm), **p = 0.0048 (80 μm), **p = 0.0023 (100 μm), by unpaired Student’s t test. (E) Dendrites of αRGCs visualized by wholemount immunostaining of P20 retina using an SMI-32 antibody in vivo. Dendrite traces were drawn for the corresponding RGCs shown. Scale bar: 20 μm. (F) Quantification of dendrite branching of SMI-32+αRGCs (E) using Sholl analysis. Data are mean ± SEM. Numbers of interactions are significantly greater in Six3-cre+/-,Ythdf2fl/fl groups (n = 14 RGCs) than Ythdf2fl/fl groups (n = 22 RGCs) in Sholl radii between 40 and 140 μm: **p = 0.0044 (40 μm), **p = 0.0035 (50 μm), ***p = 0.00021 (60 μm), ****p = 2.63E-05 (70 μm), ****p = 2.38E-06 (80 μm), ****p = 1.68E-06 (90 μm), ****p = 6.76E-06 (100 μm), ****p = 5.72E-05 (110 μm), **p = 0.0011 (120 μm), **p = 0.0032 (130 μm), *p = 0.047 (140 μm), by unpaired Student’s t test.

In the retina, RGCs target their dendrites in different sublaminae of the inner plexiform layer (IPL). Since the IPL sublaminar targeting of RGC dendrites is critical for normal visual functions, we wondered whether the increased dendrite branching caused by Ythdf2 cKO was also accompanied by altered sublaminar patterning of RGC dendrites. We used a Thy1-GFP reporter (line O) which labels a few RGCs (Feng et al., 2000). As shown in Figure 3—figure supplement 1F,G, GFP intensity is generally higher in IPL of the Ythdf2 cKO retina compared with their littermate controls, which further proves the increased RGC dendrite branching and density. However, the sublaminar pattern of GFP signals looks similar between cKO and littermate control (Figure 3—figure supplement 1F,G). Sublaminar dendrite patterning of the ipRGC subtype visualized by immunostaining of melanopsin also demonstrated the similar phenotype (Figure 3—figure supplement 1H,I). These data suggest that YTHDF2 has a general control of RGC dendrite branching but has no striking effect on the sublaminar targeting of RGC dendrite. These results are consistent with the previous findings that the RGC dendrite targeting is determined genetically and several transcription factors controlling laminar choice have been identified in RGCs and amacrine cells (Cherry et al., 2011; Kay et al., 2011b; Lefebvre et al., 2015; Liu et al., 2018).

IPL of Ythdf2 cKO retina is thicker and has more synapses

The increased dendrite branching of RGCs further prompted us to check whether Ythdf2 cKO changes IPL development. Immunostaining of P6 retina vertical sections using a MAP2 antibody demonstrated that IPL thickness significantly increased in Ythdf2 cKO retina (Figure 4A and B). As a control, the thicknesses of other retinal layers showed no difference between the Ythdf2 cKO and control mice (Figure 4—figure supplement 1A-D). Quantification of MAP2 IF intensity in IPL suggested that the IPL of Ythdf2 cKO retina became denser with dendrites (Figure 4A and C). These results suggest that the increased dendrite branching results in a thicker and denser IPL in the Ythdf2 cKO retina.

Figure 4 with 1 supplement see all
Inner plexiform layer (IPL) of the Ythdf2 conditional knockout (cKO) retina is thicker and has more synapses.

(A) Cross-sections of P6 Six3-cre+/-,Ythdf2fl/fl retina showing increased IPL thickness by MAP2 staining compared with littermate control. ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, granule cell layer. Scale bar: 20 μm. (B, C) Quantification showing increased IPL thickness and MAP2 IF intensity per area in IPL of the Ythdf2 cKO retina (A). Quantification data are represented as box and whisker plots: ****p = 1.28E-07 for B (n = 12 sections for each genotype), by unpaired Student’s t test; **p = 0.0045 for C (n = 12 sections for each genotype), by paired Student’s t test. (D, E) Representative confocal images showing the excitatory synapses labeled by colocalization of Bassoon (presynaptic) and PSD-95 (postsynaptic) in the IPL of P30 retina (D). There are significantly more synapses in the Ythdf2 cKO IPL compared with control. Quantification data are represented as box and whisker plots (E): n = 47 confocal fields for Ythdf2fl/fl, n = 23 confocal fields for Six3-cre+/-,Ythdf2fl/fl; ****p = 1.63E-05; by unpaired Student’s t test. Scale bars: 10 μm (D) and 5 μm (inset in D).

The IPL of retina is concentrated with synaptic connections, which contain synapses among and between bipolar-amacrine-ganglion cells. The increased RGC dendrite branching and denser IPL in the Ythdf2 cKO retina prompted us to wonder whether there are changes in synaptic connections in IPL. We used co-staining of the presynaptic marker Bassoon and the postsynaptic marker PSD-95 to count the colocalization puncta of Bassoon+/PSD-95+. We found that the numbers of Bassoon+/PSD-95+ excitatory synapses in IPL of Ythdf2 cKO retina are significantly larger than that of control retina (Figure 4D and E). As a control, the numbers of the excitatory ribbon synapses marked by the colocalization of Bassoon+/PSD-95+ in OPL (outer plexiform layer) show no difference between Ythdf2 cKO and control retinas (Figure 4—figure supplement 1E,F).

All these data verify that the IPL of Ythdf2 cKO retina is thicker and has more synapses.

Visual acuity is improved for the Ythdf2 cKO mice

The features of RGC dendrites, including their size, shape, arborization pattern, and localization, influence the amount and type of synaptic inputs that RGCs receive, which in turn determine how RGCs respond to specific visual stimuli such as the direction of motion (Liu and Sanes, 2017). The increased dendrite branching, the thicker and denser IPL, and the more synapses in the IPL inspired us to further explore whether the visual responses of the Ythdf2 cKO mice were changed or not. Ythdf2 cKO mice looked normal and had similar body weight and size compared with control mice for either sex (male in Figure 5A and B; female in Figure 5C and D). The generally normal development of Ythdf2 cKO mice is consistent with the specific and limited expression of Six3-cre in retina (Figure 5—figure supplement 1A), and only sparse spots in ventral forebrain (Figure 5—figure supplement 1B; Furuta et al., 2000). We used an optomotor response (OMR)-based assay (Prusky et al., 2004; Umino et al., 2008; Shi et al., 2018) to monitor visual functions of Ythdf2 cKO mice (Figure 5E). Surprisingly, the Ythdf2 cKO mice showed modestly improved visual acuity compared with the control mice, measuring spatial frequency threshold as 0.45 ± 0.0043 c/deg (cycle per degree) and 0.43 ± 0.0085 c/deg, respectively (Figure 5F, male mice). Similar phenotype was observed in female mice (Figure 5G). These results suggest that the visual acuity is modestly improved in the Ythdf2 cKO mice.

Figure 5 with 1 supplement see all
Visual acuity is improved for the Ythdf2 conditional knockout (cKO) mice.

(A–D) Six3-Cre-mediated Ythdf2 cKO showing normal animal development and body weight (male in A, female in C). Quantification data of body weight (B, D) are represented as box and whisker plots: p = 0.41 in B (male, n = 24 for control, n = 18 for cKO); P = 0.08 in D (female, n = 23 for control, n = 25 for cKO); ns, not significant; by unpaired Student’s t test. (E) The setup of optomotor response assay is illustrated by schematic drawing. (F, G) Optomotor response assay demonstrating improved visual acuity in the Ythdf2 cKO mice. Quantification data are mean ± SEM: *p = 0.048 in F (male, n = 24 control, n = 16 cKO); *p = 0.015 in G (female, n = 21 control, n = 25 cKO); by unpaired Student’s t test.

This phenotype is most likely attributed to the increased RGC dendrite branching and thicker and denser IPL with more synapses because all other parts and processes of retina are not affected except RGC dendrite in the Ythdf2 cKO mediated by Six3-cre (Figure 2—figure supplement 1 and Figure 4—figure supplement 1). The eyes and optic fibers also showed no difference between Ythdf2 cKO and control mice (Figure 5—figure supplement 1C-E). We further checked the targeting of optic nerves to the brain by anterograde labeling with cholera toxin subunit B (CTB) and found no difference of retinogeniculate or retinocollicular projections between Ythdf2 cKO and control mice (Figure 5—figure supplement 1F, G), suggesting the guidance and central targeting of RGC axons are not affected in the Ythdf2 cKO.

YTHDF2 target mRNA were identified with transcriptomic and proteomic analysis

Next, we continued to explore the underlying molecular mechanisms of the effects on dendrite branching caused by Ythdf2 cKO in the retina. First, we wanted to know what transcripts YTHDF2 recognizes and binds. We carried out anti-YTHDF2 RNA immunoprecipitation (RIP) in the retina followed by RNA sequencing of the elute (RIP-Seq). Two biological replicates of anti-YTHDF2 RIP-Seq identified 1638 transcripts (Supplementary file 1). Functional annotation of YTHDF2 RIP targets revealed significant enrichment in cellular component terms such as neuron part and neuron projection, and biological process terms such as cellular component organization and neuron projection development. We further zoomed in to check neural terms in cellular component (Figure 6A) and biological process (Figure 6B). We found that substantial numbers of YTHDF2 target transcripts are involved in cytoskeleton, dendrite, and their organization and development (Figure 6A and B), which is consistent with the dendrite branching phenotype observed in the Ythdf2 cKO retina.

YTHDF2 target mRNAs were identified with transcriptomic and proteomic analysis.

(A, B) Gene Ontology (GO) analysis of YTHDF2 target transcripts identified by anti-YTHDF2 RNA immunoprecipitation (RIP) in the retina followed by RNA sequencing (RIP-Seq). Neural terms were picked out in cellular component (A) and biological process (B). (C) GO analysis of proteins which are upregulated after YTHDF2 knockodwn (KD) by mass spectrometry (MS). (D) Verification of N6-methyladenosine (m6A) modification of YTHDF2 target mRNAs by anti-m6A pulldown followed by RT-qPCR. ND, not detected. Data are mean ± SEM and are represented as dot plots (n = 3 replicates): **p = 0.0016 for Kalrn7; ****p = 1.40E-08 for Kalrn9; ****p = 1.46E-06 for Kalrn12; ****p = 5.46E-06 for Strn; ****p = 4.90E-06 for Ubr4; by unpaired Student’s t test.

The working model for YTHDF2 is that it binds and destabilizes its m6A-modified target transcripts (Wang et al., 2014). Since the destabilization of mRNAs will eventually decrease their protein levels, we carried out proteome analysis using mass spectrometry (MS) in acute shYthdf2-mediated KD of cultured RGCs, in order to identify directly affected targets. Three biological replicates of YTHDF2 KD followed by MS (YTHDF2 KD/MS) identified 114 proteins which were upregulated by YTHDF2 KD (Supplementary file 2). Functional annotation of these proteins revealed significant enrichment in neuron development- and cytoskeleton-related terms (Figure 6C), which is similar to anti-YTHDF2 RIP-Seq results.

By overlapping the two gene lists screened from anti-YTHDF2 RIP-Seq (Supplementary file 1) and YTHDF2 KD/MS_upregulation (Supplementary file 2), we identified a group of potential YTHDF2 target mRNAs in RGCs (Supplementary file 3), including Kalrn, Strn, and Ubr4. m6A modification of these mRNAs was verified by anti-m6A pulldown (Figure 6D). Kalrn (Kalirin) gene generates three alternative splicing isoforms Kalrn7, Kalrn9, and Kalrn12 encoding guanine-nucleotide exchange factors for Rho GTPases, which have been shown to regulate hippocampal and cortical dendritic branching (Xie et al., 2010; Yan et al., 2015), and are required for normal brain functions (Penzes et al., 2001; Xie et al., 2007; Cahill et al., 2009; Russell et al., 2014; Lu et al., 2015; Herring and Nicoll, 2016). Strn (Striatin) was first identified in striatum, and functions as a B subunit of the serine/threonine phosphatase PP2A and is also a core component of a multiprotein complex called STRIPAK (striatin-interacting phosphatase and kinase complex) (Benoist et al., 2006; Li et al., 2018). Strn was reported to regulate dendritic arborization only in striatal neurons but not in cortical neurons (Li et al., 2018). However, whether and how Kalrn and Strn work in the retina was still unknown. Ubr4 (ubiquitin protein ligase E3 component N-recognin 4) is also known as p600 and has been shown to play roles in neurogenesis, neuronal migration, neuronal signaling, and survival (Parsons et al., 2015). However, whether Ubr4 regulates dendrite development remains elusive.

YTHDF2 controls the stability of its target mRNAs which encode proteins regulating RGC dendrite branching

MS analysis after YTHDF2 KD has shown that the protein levels of these target mRNAs were upregulated (Supplementary file 2). IF using antibodies against Strn and Ubr4 detected specific signals in the IPL which were increased in Ythdf2 cKO retina compared with control retina (Figure 7—figure supplement 1A). Enrichment of these proteins in IPL implies that these proteins might function locally in RGC dendrites to regulate dendrite development.

We next wanted to know whether YTHDF2 controlled the protein levels of these m6A-modified target mRNAs through regulation of translation or transcript stability. As shown in Figure 7—figure supplement 1B-E, the mRNA levels of Kalrn7, Kalrn9, Kalrn12, Strn, and Ubr4 were dramatically increased after KD of YTHDF2, KO of Ythdf2, or KD of METTL14, supporting that YTHDF2 might regulate stability of these target mRNAs. We further evaluated potential changes in the stability of these target mRNAs in an m6A-dependent manner. We further verified this by directly measuring the stability of these target mRNAs. As shown in Figure 7A, all the target mRNAs showed significantly increased stability in the Ythdf2 cKO retina compared with controls. These results suggest that YTHDF2 controlled the protein levels of its m6A-modifed target mRNAs by decreasing their stability.

Figure 7 with 1 supplement see all
YTHDF2 target mRNAs mediate YTHDF2-controlled retinal ganglion cell (RGC) dendrite branching.

(A) YTHDF2 target mRNAs showing increased stability in the Ythdf2 conditional knockout (cKO) retina. RGCs dissected from E14.5 Ythdf2 cKO and control embryos were cultured, treated with actinomycin D (ActD), and collected at different timepoints. Data are mean ± SEM (n = 3 replicates). For Kalrn7, **p = 0.0057 (3 hr), *p = 0.014 (6 hr), ***p = 0.00039 (12 hr); for Kalrn9, **p = 0.0036 (3 hr), ***p = 0.00090 (6 hr), *p = 0.032 (12 hr); for Kalrn12, **p = 0.0012 (3 hr), *p = 0.010 (6 hr), **p = 0.0069 (12 hr); for Strn, *p = 0.014 (3 hr), *p = 0.012 (6 hr), *p = 0.016 (12 hr); for Ubr4, **p = 0.0077 (3 hr), **p = 0.0059 (6 hr), *p = 0.041 (12 hr); all by unpaired Student’s t test. (B) Knockdown (KD) of the target mRNAs causing decreased dendrite branching of cultured RGCs prepared from wild type (WT) E14.5 retina by Sholl analysis. Brn3a and MAP2 IF were used to mark RGCs and visualize dendrites. Data are mean ± SEM. For Kalrn7 (n = 59 for siCtrl, n = 56 for siKalrn7), ****p = 2.33E-06 (10 μm), ****p = 5.85E-06 (15 μm), ****p = 8.67E-05 (20 μm), **p = 0.0045 (25 μm), **p = 0.0058 (30 μm), *p = 0.010 (35 μm); for Kalrn9 (n = 59 for siCtrl, n = 46 for siKalrn9), ****p = 3.69E-05 (10 μm), ****p = 5.53E-05 (15 μm), ***p = 0.00020 (20 μm), ****p = 3.09E-06 (25 μm), ****p = 4.63E-06 (30 μm), ***p = 0.00059 (35 μm), **p = 0.0010 (40 μm), *p = 0.042 (45 μm); for Kalrn12 (n = 59 for siCtrl, n = 39 for siKalrn12), **p = 0.0031 (10 μm), ***p = 0.00017 (15 μm), ****p = 6.56E-05 (20 μm), **p = 0.0017 (25 μm), *p = 0.017 (30 μm); for Strn (n = 51 for siCtrl, n = 57 for siStrn), ****p = 4.19E-05 (10 μm), ***p = 0.00067 (15 μm), **p = 0.0079 (20 μm), *p = 0.015 (30 μm); for Ubr4 (n = 81 for siCtrl, n = 81 for siUbr4), ****p = 1.26E-08 (10 μm), ****p = 7.61E-10 (15 μm), ****p = 2.35E-08 (20 μm), ****p = 1.39E-05 (25 μm), **p = 0.0061 (30 μm); all by unpaired Student’s t test. (C) Increased dendrite branching of cultured RGCs prepared from E14.5 Ythdf2 cKO (Y2 cKO) retina was rescued by KD of target mRNAs using siRNAs. Data are mean ± SEM. Ctrl, Ythdf2fl/fl; Y2 cKO, Six3-cre+/-,Ythdf2fl/fl. In C1,'Ctrl, siCtrl’ (n = 35 neurons) vs. ‘Y2 cKO, siCtrl’ (n = 52 neurons), *p = 0.038 (15 μm), *p = 0.045 (20 μm), **p = 0.0036 (30 μm); ‘Y2 cKO, siKalrn7’ (n = 55 neurons) vs. ‘Y2 cKO, siCtrl’, *p = 0.020 (15 μm), *p = 0.025 (20 μm), *p = 0.031 (25 μm); ‘Y2 cKO, siKalrn9’ (n = 66 neurons) vs. ‘Y2 cKO, siCtrl’, *p = 0.020 (10 μm), *p = 0.013 (15 μm), *p = 0.031 (20 μm), *p = 0.017 (25 μm), *p = 0.031 (30 μm), *p = 0.031 (45 μm); ‘Y2 cKO, siKalrn12’ (n = 80 neurons) vs. ‘Y2 cKO, siCtrl’, *p = 0.015 (10 μm), **p = 0.0018 (15 μm), *p = 0.015 (20 μm), *p = 0.027 (40 μm). In C2, 'Ctrl, siCtrl’ (n = 50 neurons) vs. ‘Y2 cKO, siCtrl’ (n = 47 neurons), **p = 0.0031 (10 μm), **p = 0.0013 (15 μm), *p = 0.029 (20 μm), **p = 0.0015 (30 μm), *p = 0.014 (35 μm); ‘Y2 cKO, siStrn’ (n = 45 neurons) vs. ‘Y2 cKO, siCtrl’, ***p = 0.00016 (10 μm), **p = 0.0043 (15 μm), *p = 0.010 (20 μm), *p = 0.018 (30 μm); ‘Y2 cKO, siUbr4’ (n = 57 neurons) vs. ‘Y2 cKO, siCtrl’, ***p = 0.00084 (10 μm), ****p = 4.89E-05 (15 μm), **p = 0.0058 (20 μm), **p = 0.0045 (30 μm). All by unpaired Student’s t test. (D) Increased dendrite branching of RGC subtypes in Ythdf2 cKO (Y2 cKO) retina was rescued by KD of target mRNAs through intravitreal injection of AAV shRNAs in vivo. Data are mean ± SEM. Ctrl, Ythdf2fl/fl; Y2 cKO, Six3-cre+/-,Ythdf2fl/fl. In D1 (CART+/eGFP+ ooDSGCs), ‘Ctrl, shCtrl’ (n = 10 neurons) vs. ‘Y2 cKO, shCtrl’ (n = 6 neurons), *p = 0.010 (10 μm), ***p = 0.00049 (20 μm), **p = 0.0021 (30 μm), **p = 0.0047 (40 μm), *p = 0.028 (50 μm), *p = 0.011 (60 μm), *p = 0.030 (90 μm), *p = 0.042 (110 μm); ‘Y2 cKO, shKalrn12’ (n = 8 neurons) vs. ‘Y2 cKO, shCtrl’, *p = 0.012 (20 μm), *p = 0.014 (30 μm); ‘Y2 cKO, shUbr4’ (n = 6 neurons) vs. ‘Y2 cKO, shCtrl’, *p = 0.011 (10 μm), **p = 0.0084 (20 μm), *p = 0.029 (30 μm). In D2 (SMI-32+αRGCs), ‘Ctrl, shCtrl’ (n = 14 neurons) vs. ‘Y2 cKO, shCtrl’ (n = 14 neurons), *p = 0.032 (40 μm), **p = 0.0019 (50 μm), **p = 0.0014 (60 μm), *p = 0.015 (70 μm), *p = 0.044 (90 μm); ‘Y2 cKO, shKalrn12’ (n = 26 neurons) vs. ‘Y2 cKO, shCtrl’, **p = 0.0023 (20 μm), ***p = 0.00076 (30 μm), ***p = 0.00030 (40 μm), ***p = 0.00020 (50 μm), *p = 0.015 (60 μm); ‘Y2 cKO, shUbr4’ (n = 15 neurons) vs. ‘Y2 cKO, shCtrl’, *p = 0.042 (30 μm), *p = 0.024 (40 μm), *p = 0.018 (50 μm). All by unpaired Student’s t test.

Next we explored the functions of these YTHDF2 target mRNAs in RGC dendrite development. We first generated siRNAs against these transcripts (Figure 7—figure supplement 1F). We then checked the effects on RGC dendrite branching after KD of these target mRNAs by siRNAs in cultured RGCs. As shown in Figure 7B, KD of Kalrn7, Kalrn9, Kalrn12, Strn, or Ubr4 led to significant decreases of RGC dendrite branching. Interestingly, the siCocktail against all these target mRNAs further significantly reduced the RGC dendrite branching compared with each individual siRNA (Figure 7—figure supplement 1G), suggesting that these targets may work in different pathways to regulate the RGC dendrite morphology. We further examined whether these target mRNAs mediate YTHDF2-regulated RGC dendrite branching. As shown in Figures 2E–H ,3, cKO of Ythdf2 led to increased dendrite branching of RGCs both in vitro and in vivo. Transfection of siRNAs against these target mRNAs rescued dendrite branching increases in cultured Ythdf2 cKO RGCs (Figure 7C). We continued to generate and performed intravitreal injection of AAV viral shKalrn12 and shUbr4, which significantly rescued dendrite branching increases of CART+ ooDSGCs and SMI-32+αRGCs in Ythdf2 cKO retina in vivo (Figure 7D).

Taken together, we identified a group of YTHDF2 target mRNAs that encode proteins regulating RGC dendrite branching, which mediate YTHDF2-controlled RGC dendrite branching.

Ythdf2 cKO retina is more resistant to AOH

The glaucomatous eyes are symptomatized with progressive neurodegeneration and vision loss (Agostinone and Di Polo, 2015). High intraocular pressure is a major risk factor in glaucoma and has been shown to cause pathological changes in RGC dendrites before axon degeneration or soma loss is detected in different model animals (Weber et al., 1998; Shou et al., 2003; Morgan et al., 2006). Our findings that Ythdf2 cKO in retina promotes RGC dendrite branching during development inspired us to wonder whether YTHDF2 also regulates RGC dendrite maintenance in the acute glaucoma model caused by AOH. We utilized the AOH model made with control and Ythdf2 cKO mice to check whether Ythdf2 cKO in the retina could alter the pathology in the glaucomatous eyes. RGC dendrite branching is significantly decreased after AOH operation compared with non-AOH in either genotype (Figure 8—figure supplement 1A,B). Interestingly, the Ythdf2 cKO retina with AOH operation maintains significantly higher dendrite complexity compared with the glaucomatous eyes of Ythdf2fl/fl control mice (Figure 8A and B). In addition, there are significant RGC neuron losses in both genotypes after AOH (Figure 8C and D). However, the reduction of RGC number in the Ythdf2 cKO retina is less than control retina (Figure 8C and D). These results support that Ythdf2 cKO protects retina from RGC dendrite degeneration and soma loss caused by AOH.

Figure 8 with 1 supplement see all
Ythdf2 conditional knockout (cKO) retina is more resistant to acute ocular hypertension (AOH).

(A, B) Better maintenance of retinal ganglion cell (RGC) dendrite arborization in Ythdf2 cKO retina after AOH operation. AOH was performed using adult mice, and retinas were collected after AOH for wholemount immunostaining of melanopsin and SMI-32 to visualize the dendrite arbors of corresponding RGC subtype, respectively. Dendrite traces were drawn as previously shown and quantification of dendrite branching was done using Sholl analysis. Data are mean ± SEM. Numbers of interactions are significantly greater in Six3-cre+/-,Ythdf2fl/fl retina than Ythdf2fl/fl control retina in both RGC subtypes after AOH: for melanopsin+ intrinsically photosensitive RGCs (ipRGCs) in A, Ythdf2fl/fl/AOH (n = 51 RGCs) vs. cKO/AOH (n = 64 RGCs), ***p = 0.00015 (10 μm), **p = 0.0017 (20 μm), *p = 0.034 (30 μm), ***p = 0.00035 (40 μm), ****p = 3.02E-05 (50 μm), ****p = 2.63E-05 (60 μm), **p = 0.0029 (70 μm), **p = 0.0028 (80 μm), ***p = 0.00035 (90 μm), **p = 0.0032 (100 μm), **p = 0.0014 (110 μm), **p = 0.0043 (120 μm), **p = 0.0014 (130 μm), *p = 0.023 (140 μm), *p = 0.013 (150 μm); for SMI-32+αRGCs in B, Ythdf2fl/fl/AOH (n = 21 neurons) vs. cKO/AOH (n = 15 neurons), **p = 0.0052 (40 μm), **p = 0.0057 (50 μm); all by unpaired Student’s t test. (C, D) Ythdf2 cKO retina showing less severe RGC loss after AOH. AOH was performed using adult mice and retinas were collected after AOH for wholemount immunostaining using a Brn3a antibody (C). Numbers of Brn3a+ RGCs per 10,000 μm2 of retina were quantified for different genotypes and conditions (confocal fields for analysis: n = 117 for Ythdf2fl/fl/Ctrl; n = 98 for Ythdf2fl/fl/AOH; n = 110 for cKO/Ctrl; n = 104 for cKO/AOH). Data are represented as box and whisker plots (D): ns, not significant (p = 0.16; Ythdf2fl/fl/Ctrl vs. cKO/Ctrl); **p = 0.0077 (Ythdf2fl/fl/AOH vs. cKO/AOH); by unpaired Student’s t test. Scale bar: 25 μm. (E, F) Overexpression (OE) of YTHDF2 targets Hspa12a and Islr2 protecting retina from RGC dendrite degeneration in the AOH model. Wild type (WT) mice were intravitreally injected with AAV overexpressing Hspa12a or Islr2 and then operated with AOH. Wholemount immunostaining of CART/ZsGreen and SMI-32/ZsGreen was carried out to visualize the dendrite arbors of corresponding RGC subtype, respectively. Dendrite traces were drawn as previously shown and quantification of dendrite branching was done using Sholl analysis. Data are mean ± SEM. Numbers of interactions are significantly greater in retina with OE of Hspa12a or Islr2 than control retina in both RGC subtypes after AOH. For CART+ ON-OFF directionally selective RGCs (ooDSGCs) in E: OE-Ctrl/AOH (n = 11 RGCs) vs. OE-Hspa12a/AOH (n = 11 RGCs), *p = 0.014 (20 μm), **p = 0.0025 (30 μm), *p = 0.018 (40 μm); OE-Ctrl/AOH vs. OE-Islr2/AOH (n = 6 RGCs), *p = 0.024 (10 μm), ***p = 0.00031 (20 μm), **p = 0.0038 (30 μm), *p = 0.013 (40 μm). For SMI-32+αRGCs in F: OE-Ctrl/AOH (n = 49 neurons) vs. OE-Hspa12a/AOH (n = 46 neurons), **p = 0.0023 (30 μm), ***p = 0.00080 (40 μm), **p = 0.0059 (50 μm), **p = 0.0051 (60 μm), **p = 0.0036 (70 μm), ***p = 0.00070 (80 μm), **p = 0.0015 (90 μm), *p = 0.016 (100 μm), *p = 0.011 (110 μm); OE-Ctrl/AOH vs. OE-Islr2/AOH (n = 13 RGCs), *p = 0.010 (30 μm), **p = 0.0093 (40 μm), **p = 0.0019 (50 μm), ***p = 0.00085 (60 μm), ***p = 0.00067 (70 μm), ****p = 4.25E-05 (80 μm), ****p = 2.54E-05 (90 μm), ***p = 0.00020 (100 μm) , **p = 0.0016 (110 μm). All by unpaired Student’s t test. (G) OE of YTHDF2 targets Hspa12a and Islr2 alleviating RGC loss in the AOH model. WT mice were intravitreally injected with AAV overexpressing Hspa12a or Islr2 and then operated with AOH. Wholemount immunostaining of Brn3a was performed to label RGCs. Numbers of Brn3a+ RGCs per 10,000 μm2 of retina were quantified for different conditions (confocal fields for analysis: n = 19 for OE-Ctrl; n = 26 for OE-Hspa12a; n = 24 for OE-Islr2). Data are represented as box and whisker plots: *p = 0.034 (OE-Hspa12a vs. OE-Ctrl; *p = 0.029 (OE-Islr2 vs. OE-Ctrl); by unpaired Student’s t test.

Next we wanted to know whether and how YTHDF2 target mRNAs mediate these effects in the AOH models. We first checked the expression of YTHDF2 target mRNAs identified in the developing retina (Supplementary file 3) in the adult Ythdf2 cKO and control retina. We found that two target mRNAs Hspa12a and Islr2 show upregulation in the adult Ythdf2 cKO retina compared with control (Figure 8—figure supplement 1C). m6A modification of Hspa12a and Islr2 mRNAs was further verified by anti-m6A pulldown (Figure 8—figure supplement 1D). Hspa12a encodes heat shock protein A12A which is an atypical member of the heat shock protein 70 family and has been shown to be downregulated in diseases such as ischemic stroke, schizophrenia, and renal cell carcinoma (Pongrac et al., 2004; Mao et al., 2018; Min et al., 2020). Islr2 encodes immunoglobulin superfamily containing leucine-rich repeat protein two and is poorly studied. Here, we found that Hspa12a and Islr2 are downregulated in the retina after AOH operation (Figure 8—figure supplement 1E), which is likely caused by upregulation of YTHDF2 in the AOH-treated retina (Figure 8—figure supplement 1F-H). We therefore hypothesized that AOH upregulates YTHDF2 which in turn downregulates its targets Hspa12a and Islr2, thus causing RGC dendrite degeneration and soma loss. If this is the case, overexpression of Hspa12a and Islr2 might protect RGC dendrite from AOH-triggered degeneration. We thus generated AAV harboring overexpression constructs of Hspa12a and Islr2 which were intravitreally injected to wild type retinas. After the AOH induction, the retinas overexpressing Hspa12a and Islr2 maintain significantly more complex RGC dendrite arbor and show better RGC survival compared with control AAV (Figure 8E–G).

These data verify that loss-of-function of YTHDF2 and gain-of-function of its targets Hspa12a and Islr2 have neuroprotective roles in the glaucomatous retina.

Discussion

Functions and mechanisms of mRNA m6A modification in the dendrite development were not known. Here, we revealed a critical role of the m6A reader YTHDF2 in RGC dendrite development and maintenance. YTHDF2 have two phases of function to control RGC dendrite development first and then maintenance through regulating two sets of target mRNAs. In early postnatal stages, the target mRNAs Kalrn7, Kalrn9, Kalrn12, Strn, and Ubr4 mediate YTHDF2 functions to regulate RGC dendrite development. In the adult mice, another set of target mRNAs Hspa12a and Islr2 mediate YTHDF2 function to regulate RGC dendrite maintenance.

Positive and negative regulators for dendrite development

The general principle for dendrite arborization is that the dendrite arbor cannot be either too big or too small in order to precisely sample a presynaptic target area during neural circuit formation (Lefebvre et al., 2015). Numerous extrinsic and intrinsic mechanisms have been found to regulate dendritic arbor patterning, which involves both positive and negative factors to achieve balanced control of dendritic growth (Jan and Jan, 2010; Dong et al., 2015; Ledda and Paratcha, 2017). For the secreted and diffusible cues, BDNF promotes dendrite branching and complexity (Cheung et al., 2007); the non-canonical Wnt7b/PCP pathway is a positive regulator of dendrite growth and branching (Rosso et al., 2005); the non-canonical Wnt receptor Ryk works as a negative regulator by limiting the extent of dendritic branching (Lanoue et al., 2017). For the contact-mediated signals, the cadherins Celsr2 and Celsr3 regulate dendrite growth in an opposite manner in cortical pyramidal and Purkinje neurons, and hippocampal neurons, respectively (Shima et al., 2004; Shima et al., 2007). For the transcription factors, studies have shown that manipulation of Cux1 and Cux2 levels has distinct effects on apical and basal arbors of cortical dendrites (Cubelos et al., 2015); interestingly, the functions of Sp4 in dendrite development are dependent on the cellular context of its expression, for example, Sp4 promotes dendrite growth and branching in hippocampal dentate granule cells but limits dendrite branching in cerebellar granule cells (Ramos et al., 2007; Zhou et al., 2007). Here, we identified another negative regulator YTHDF2 which works posttranscriptionally, and loss-of-function of YTHDF2 increased dendrite complexity during development and protected RGC degeneration from AOH. We have validated this effect on several RGC subtypes. Since there are dozens of RGC subtypes, it is technically challenging but still interesting to test whether this effect is universal to all subtypes or there is specificity for RGC subtypes.

Posttranscriptional regulation of dendrite development

It is well established that mRNAs can be transported and targeted to specific neuronal compartments such as axons and dendrites. Local translation of these mRNAs enables exquisite and rapid control of local proteome in specific subcellular compartments (Ledda and Paratcha, 2017). Local translation is known to play roles in controlling dendrite arborization (Chihara et al., 2007), and is regulated by specific RNA-binding proteins (Jan and Jan, 2010). In Drosophila, the RNA-binding proteins Pumilio (Pum), Nanos (Nos), Glorund (Glo), and Smaug (Smg) regulate morphogenesis and branching of specific classes of dendritic arborization neurons through controlling translation of their target mRNAs including nanos mRNA itself (Ye et al., 2004; Brechbiel and Gavis, 2008). The mouse homologue of another RNA-binding protein Staufen, Stau1, regulates dendritic targeting of ribonucleoprotein particles and dendrite branching (Vessey et al., 2008). Here, we found that the m6A reader and RNA-binding protein YTHDF2 control stability of its target mRNAs and regulate dendrite branching in RGCs. It would be interesting to see whether these target mRNAs are localized into dendrites and whether YTHDF2 works in dendrites to control their stability and translation. Actually, Strn4 mRNA has been shown to be present in dendrites and locally translated (Lin et al., 2017). In addition, how the proteins encoded by these target mRNAs regulate RGC dendrite branching during development and maintenance remains to be explored and will be important future directions.

Neuroprotective genes in retinal injuries and degeneration

Transcriptome analyses have revealed differentially expressed genes after retinal injuries such as AOH-induced glaucoma and optic nerve crush (ONC), and the upregulated genes are of importance for discovering new treatment approaches (Jakobs, 2014; Tran et al., 2019). One of the previous studies has identified Mettl3, encoding the m6A writer, as an upregulated gene after ONC (Agudo et al., 2008). Here, we found Ythdf2, encoding an m6A reader, was also upregulated in the retina after AOH. We further found that Hspa12a and Islr2, two targets of YTHDF2 in adult retina, were downregulated in glaucomatous retinas. Overexpression of Hspa12a and Islr2 protected retina from AOH-caused RGC dendrite degeneration. Our findings in this study suggest that YTHDF2 and its neuroprotective target mRNAs might be valuable in developing novel therapeutic approaches to treat neurodegeneration caused by glaucoma and other retinal injuries.

Materials and methods

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Strain, strain background (mouse)Mouse: Ythdf2fl/flYu et al., 2021bN/A
Strain, strain background (mouse)Mouse: Tg(Six3-cre)69Frty/GcoJJackson LaboratoryCat#: JAX_019755RRID: IMSR_JAX:019755
Strain, strain background (mouse)Mouse: B6.Cg-Tg(Thy1-EGFP)OJrs/GfngJJackson LaboratoryCat#: JAX_007919RRID: IMSR_JAX:007919
Strain, strain background (mouse)Mouse: B6.129 × 1-Gt(ROSA)26Sortm1(EYFP)Cos/JJackson LaboratoryCat#: JAX_006148RRID: IMSR_JAX:006148
AntibodyAnti-GFP (Chicken polyclonal)AbcamCat#: ab13970,
RRID: AB_300798
IF (1:1000)
AntibodyAnti-MAP2 (Chicken polyclonal)AbcamCat#: ab5392,
RRID: AB_2138153
IF (1:10,000)
AntibodyAnti-RBPMS (Guinea pig polyclonal)PhosphoSolutionsCat#: 1832-RBPMS,
RRID: AB_2492226
IF (1:1000)
AntibodyAnti-VAChT (Goat polyclonal)MilliporeCat#: ABN100, RRID: AB_2630394IF (1:1000)
AntibodyAnti-β Actin (Mouse monoclonal)AbcamCat#: ab6276,
RRID: AB_2223210
WB (1:30,000)
AntibodyAnti-β Actin (Mouse monoclonal)ABclonalCat#: AC004,
RRID: AB_2737399
WB (1:30,000)
AntibodyAnti-AP2α (Mouse monoclonal)DSHBCat#: 3B5, RRID: AB_2313947IF (1:1000)
AntibodyAnti-Bassoon (Mouse monoclonal)Enzo Life SciencesCat#: ADI-VAM-PS003, RRID: AB_10618753IF (1:2500)
AntibodyAnti-Brn3a (Mouse monoclonal)MilliporeCat#: MAB1585, RRID: AB_94166IF (1:300)
AntibodyAnti-Calbindin-D-28K (Mouse monoclonal)Sigma-AldrichCat#: C9848, RRID: AB_476894IF (1:200)
AntibodyAnti-PKCα (Mouse monoclonal)Santa Cruz BiotechnologyCat#: sc-8393, RRID: AB_628142IF (1:500)
AntibodyAnti-SMI-32 (Mouse monoclonal)BioLegendCat#: 801701, RRID: AB_2564642IF (1:200)
AntibodyAnti-Strn (Striatin) (Mouse monoclonal)BD BiosciencesCat#: 610838, RRID: AB_398157IF (1:500)
AntibodyAnti-CART (Rabbit polyclonal)Phoenix PharmaceuticalsCat#: H-003–62, RRID: AB_2313614IF (1:2000)
AntibodyAnti m6A (Rabbit polyclonal)Synaptic SystemsCat# 202003,
RRID: AB_2279214
IF (1:200)
AntibodyAnti-melanopsin (Rabbit polyclonal)Thermo Fisher ScientificCat#: PA1-780, RRID: AB_2267547IF (1:1000)
AntibodyAnti-PKCα (Rabbit polyclonal)Cell SignalingCat#: CST-2056IF (1:1000)
AntibodyAnti-PSD-95 (Mouse monoclonal)AbcamCat#: ab2723,
RRID: AB_303248
IF (1:500)
AntibodyAnti-Recoverin (Rabbit polyclonal)MilliporeCat#: AB5585,
RRID: AB_2253622
IF (1:1000)
AntibodyAnti-YTHDF2 (Rabbit polyclonal)ProteintechCat#: 24744–1-AP, RRID: AB_2687435IF (1:1000)
AntibodyAnti-YTHDF1 (Rabbit polyclonal)ProteintechCat#: 17479–1-AP, RRID: AB_2217473IF (1:1000)
AntibodyAnti-YTHDF3 (Rabbit polyclonal)AbcamCat#: ab103328, RRID: AB_10710895IF (1:1000)
AntibodyAnti-Ubr4 (Rabbit polyclonal)AbcamCat#: ab86738, RRID: AB_1952666IF (1:300)
AntibodyAnti-Chx10 (Sheep polyclonal)ExalphaCat#: X1179PIF (1:1000)
AntibodyAnti-GFAP (Chicken polyclonal)MilliporeCat#: AB5541, RRID: AB_177521IF (1:500)
AntibodyAnti-Lhx2 (Goat polyclonal)Santa Cruz BiotechnologyCat#: sc-19344, RRID: AB_2135660IF (1:200)
AntibodyAnti-Lhx2 (Rabbit monoclonal)AbcamCat#: ab184337IF (1:500)
AntibodyAnti-chicken IgY (Alexa 488 donkey)Jackson ImmunoresearchCat#: 703-545-155, RRID: AB_2340375IF (1:500)
AntibodyAnti-G. pig IgG (Alexa 488 donkey)Jackson ImmunoresearchCat#: 706-545-148, RRID: AB_2340472IF (1:500)
AntibodyAnti-mouse IgG (Alexa 488 donkey)Thermo Fisher ScientificCat#: A-21202, RRID: AB_141607IF (1:500)
AntibodyAnti-rabbit IgG (Alexa 488 donkey)Thermo Fisher ScientificCat#: A-21206, RRID: AB_141708IF (1:500)
AntibodyAnti-goat IgG (Alexa 555 donkey)Thermo Fisher ScientificCat#: A-21432, RRID: AB_2535853IF (1:1000)
AntibodyAnti-mouse IgG (Alexa 555 donkey)Thermo Fisher ScientificCat#: A-31570, RRID: AB_2536180IF (1:1000)
AntibodyAnti-rabbit IgG (Alexa 555 donkey)Thermo Fisher ScientificCat#: A-31572, RRID: AB_162543IF (1:1000)
AntibodyAnti-sheep IgG (Alexa 555 donkey)Thermo Fisher ScientificCat#: A-21436, RRID: AB_2535857IF (1:1000)
AntibodyAnti-chicken IgY (Alexa 555 goat)Thermo Fisher ScientificCat#: A-21437, RRID: AB_2535858IF (1:1000)
AntibodyAnti-mouse IgG (Alexa 647 donkey)Thermo Fisher ScientificCat#: A-31571, RRID: AB_162542IF (1:200)
AntibodyAnti-mouse IgG (HRP donkey)AbcamCat#: ab97030, RRID: AB_10680919WB (1:2500)
AntibodyAnti-rabbit IgG (HRP donkey)AbcamCat#: ab16284, RRID: AB_955387WB (1:2500)
AntibodyAnti-mouse IgG (HRP VHH)AlpaLifeCat#: KTSM1321WB (1:5000)
AntibodyAnti-rabbit IgG (HRP VHH)AlpaLifeCat#: KTSM1322WB (1:5000)
Recombinant DNA reagentPlasmid: pLKO.1-TRCAddgeneAddgene plasmid #10878, RRID: Addgene_10878
Sequence-based reagentshRNA targeting
sequence of
negative control
This paperN/AGCATCAAGGTG
AACTTCAAGA
Sequence-based reagentshRNA targeting
sequence of mouse Ythdf2
Yu et al., 2018N/AGGACGTTCCC
AATAGCCAACT
Sequence-based reagentshRNA targeting
sequence of mouse Ythdf1
This paperN/AGGACATTGGT
ACTTGGGATAA
Sequence-based reagentshRNA targeting
sequence of mouse Ythdf3
This paperN/AGGATTTGGCAA
TGATACTTTG
Sequence-based reagentshRNA targeting sequence of mouse Mettl14#6This paperN/AGCTGGACCTGG
GATGATATTA
Sequence-based reagentshRNA targeting sequence of mouse Mettl14#7This paperN/ACCCAGCTTGT
ACTTTGCTTTA
Sequence-based reagentshRNA targeting sequence of negative control (AAV)This paperN/ATTCTCCGAAC
GTGTCACGTAA
Sequence-based reagentshRNA targeting sequence of mouse Kalrn12This paperN/ATGATGAGCTGA
TGGAAGAA
Sequence-based reagentshRNA targeting sequence of mouse Ubr4This paperN/AAATGATGAGC
AGTCATCTC
Sequence-based reagentsiRNA targeting sequence of negative controlYu et al., 2018N/AUUCUCCGAAC
GUGUCACGUTT
Sequence-based reagentsiRNA targeting sequence of mouse Kalrn7Xie et al., 2007N/AAGUACAAUCCU
GGCCAUGUTT
Sequence-based reagentsiRNA targeting sequence of mouse Kalrn9Yan et al., 2015N/AACUGGACUGG
ACUUCUAUUTT
Sequence-based reagentsiRNA targeting sequence of mouse Kalrn12Yan et al., 2015N/ACGAUGAGCUG
AUGGAAGAATT
Sequence-based reagentsiRNA targeting sequence of mouse StrnBreitman et al., 2008N/AGGUGAAGAUCG
AGAUACAATT
Sequence-based reagentsiRNA targeting sequence of mouse Ubr4Shim et al., 2008N/AAAUGAUGAGC
AGUCAUCUATT
Sequence-based reagentqPCR primers of mouse 18sWang et al., 2018N/AFwd: GCTTAATTTGACT
CAACACGGGARev: AGCTATCAATCTG
TCAATCCTGTC
Sequence-based reagentqPCR primers of mouse GapdhMains et al., 2011N/AFwd: TTGTCAGCAATG
CATCCTGCACCACCRev: CTGAGTGGCAGT
GATGGCATGGAC
Sequence-based reagentqPCR primers of mouse Ythdf2This paperN/AFwd: GAGCAGAGA
CCAAAAGGTCAAGRev: CTGTGGGCTC
AAGTAAGGTTC
Sequence-based reagentqPCR primers of mouse Kalrn7Mains et al., 2011N/AFwd: GATACCATATCCAT
TGCCTCCAGGACCRev: CCAGGCTGCGC
GCTAAACGTAAG
Sequence-based reagentqPCR primers of mouse Kalrn9Mains et al., 2011N/AFwd: GCCCCTCGCC
AAAGCCACAGCRev: CCAGTGAGT
CCCGTGGTGGGC
Sequence-based reagentqPCR primers of mouse Kalrn12Mains et al., 2011N/AFwd: CAGCAGCCA
CGTGCCTGCAGCRev: TCTTGACATTGGG
AATGGGCCGCAC
Sequence-based reagentqPCR primers of mouse StrnThis paperN/AFwd: TGAAGCCTG
GAATGTGGACCRev: CTATTGGGC
CTCTTCACCCC
Sequence-based reagentqPCR primers of mouse Ubr4This paperN/AFwd: TGAGTGAGG
ACAAGGGCAACRev: GGGTTGGAT
CGAACGAAGGT
Sequence-based reagentqPCR primer for mouse Hspa12aThis paperN/AFwd: GGGTTTGCACA
GGCTAAGGARev: TCTGATGGACG
GTCAGGTCT
Sequence-based reagentqPCR primer for mouse Islr2This paperN/AFwd: GAAGCTCCCTTA
GACTGTCACCRev: CCCCATCGTGA
CTCCTGCTG
Sequence-based reagentPCR primer for mouse Hspa12a CDSThis paperN/AFwd: ATGGCGGACAA
GGAAGCTGGRev: GTAATTTAAGAA
GTCGATCCCC
Sequence-based reagentPCR primer for mouse Islr2 CDSThis paperN/AFwd: ATGGGGCC
CTTTGGAGCRev: GCCCGCTGTC
TGCCTGTAG
Sequence-based reagentMouse genotyping primers for Ythdf2 loxp site 1This paperN/AGCTTGTAGTTATG
TTGTGTACCAC and GCAGCTCTGACT
ATTCTAAAACCTCC
Sequence-based reagentMouse genotyping primers for Ythdf2 loxp site 2This paperN/ACTCATAACATCC
ATAGCCACAGG and CCAAGAGATAG
CTTTCCTAATG
Sequence-based reagentMouse genotyping primers for Six3-creChunqiao Liu’s labN/ACCTTCCTCCCT
CTCTATGTG and GAACGAACCT
GGTCGAAATC
Sequence-based reagentMouse genotyping primers for Thy1-GFPThe Jackson Laboratory websiteN/ACGGTGGTGC
AGATGAACTT and ACAGACACAC
ACCCAGGACA
Sequence-based reagentMouse genotyping primers for Rosa-YFP mutant siteThe Jackson Laboratory websiteN/AAGGGCGAGG
AGCTGTTCA and TGAAGTCGAT
GCCCTTCAG
Sequence-based reagentMouse genotyping primers for Rosa-YFP wild type siteThe Jackson Laboratory websiteN/ACTGGCTTCT
GAGGACCG and CAGGACAAC
GCCCACACA
Peptide, recombinant proteinInsulinSigmaCat#: I6634
Peptide, recombinant proteinRecombinant Human/Murine/Rat BDNFPeproTechCat#: 450–02
Peptide, recombinant proteinRecombinant Human NT-3PeproTechCat#: 450–03
Peptide, recombinant proteinRecombinant Murine EGFPeproTechCat#: 315–09
Peptide, recombinant proteinRecombinant Human FGF-basicPeproTechCat#: 100-18B
Commercial assay or kitPierce BCA Protein Assay KitThermo Fisher ScientificCat#: 23227
Commercial assay or kitGeneSilencer Transfection ReagentGenlantisCat#: T500750
Commercial assay or kitMagna MeRIP m6A KitMilliporeCat#: 17–10499
Commercial assay or kitEZ-Magna RIP RNA-Binding Protein Immunoprecipitation KitMilliporeCat#: 17–701
Chemical compound, drugcpt-cAMP, 8-(4-Chlorophenylthio) Adenosine 3':5'-CYSigmaCat#: C3912
Chemical compound, drugN-acetyl-L-cysteine (NAC)SigmaCat#: A8199
Chemical compound, drugForskolinSigmaCat#: F6886
Chemical compound, drugPuromycinThermo Fisher ScientificCat#: A11138-03
Chemical compound, drugPuromycinSigmaCat#: P8833
Chemical compound, drugParaformaldehydeVetecCat#: V900894-100G
Chemical compound, drugTriton X-100SigmaCat#: V900502
Software, algorithmGraphPad Prism 7.0GraphPadhttps://www.graphpad.com,
RRID: SCR_002798
Software, algorithmSTAR v2.5Dobin et al., 2013https://github.com/alexdobin/STAR/
RRID:SCR_004463
Software, algorithmHTSeqAnders et al., 2015https://pypi.org/project/HTSeq/
Software, algorithmImageJ (Fiji)Schindelin et al., 2012http://fiji.sc, RRID:SCR_002285
Software, algorithmMatlabMatlabhttps://ww2.mathworks.cn
OtherTRIzol ReagentLifeCat#: 15596018
OtherPrimeScript RT Master MixTakaraCat#: RR036B
Other2× ChamQ Universal SYBR qPCR Master MixVazymeCat#: Q711-02
OtherDMEM, high glucoseGibcoCat#: 11965–092
OtherDulbecco’s Modified Eagle’s Medium, 10×, low glucoseSigmaCat#: D2429
OtherDMEM, high glucoseHycloneCat#: SH30022.01
OtherFetal Bovine Serum (FBS)GibcoCat#: 10270–106
OtherDulbecco’s Phosphate-Buffered Saline, 1× without calcium and magnesium (DPBS)CorningCat#: 21–031-CVR
OtherPoly-D-lysine, CultrexTrevigenCat#: 3439-100-01
OtherLaminin (mouse), CulrexTrevigenCat#: 3400-010-01
OtherDMEM/F-12, GlutaMAXGibcoCat#: 10565–018
OtherNeurobasal Medium, minus phenol redGibcoCat#: 12348–017
OtherPenicillin-StreptomycinLifeCat#: 15140–122
OtherB27 serum-free supplement, 50×LifeCat#: 17504044
OtherN-2 Supplement, 100×GibcoCat#: 17502–048
OtherOCT Compound and Cryomolds, Tissue-TekSAKURACat#: 4583
OtherChemiBLOCKERMilliporeCat#: 2170
OtherCTB (Cholera Toxin Subunit B) conjugated by Alexa Fluor 555InvitrogenCat#: C34776
OtherVECTASHIELD Antifade Mounting Medium with DAPIVector LaboratoryCat#: H-1200
OtherMounting Medium, antifading (with DAPI)SolarbioCat#: S2110
OtherNormal Goat SerumNovusCat#: NBP2-23475

Animals and generation of the Ythdf2 cKO mice

Request a detailed protocol

Ythdf2fl/fl mice were reported previously (Yu et al., 2021b). Six3-cre (Furuta et al., 2000), Thy1-GFP (Feng et al., 2000), and Rosa26-eYFP (Srinivas et al., 2001) mice were from Jackson Laboratory. For timed pregnancy, embryos were identified as E0.5 when a copulatory plug was observed. Genotyping primers are as following: the first Ythdf2-loxP site, 5’-GCTTGTAGTTATGTTGTGTACCAC-3’ and 5’-GCAGCTCTGACTATTCTAAAACCTCC-3’; the second Ythdf2-loxP site, 5’-CTCATAACATCCATAGCCACAGG-3’, and 5’-CCAAGAGATAGCTTTCCTAATG-3’.

Six3-cre site, 5’-CCTTCCTCCCTCTCTATGTG-3’ and 5’-GAACGAACCTGGTCGAAATC-3’.

Rosa26-eYFP wild type site, 5’-CTGGCTTCTGAGGACCG-3’ and 5’-CAGGACAACGCCCACACA-3’; the mutant site, 5’-AGGGCGAGGAGCTGTTCA-3’ and 5’-TGAAGTCGATGCCCTTCAG-3’. All experiments using mice were carried out following the animal protocols approved by the Laboratory Animal Welfare and Ethics Committee of Southern University of Science and Technology.

Retinal neuronal culture

Request a detailed protocol

Retinal neurons were dissociated from E14.5 to 15.5 mouse embryos by papain in DPBS (1× Dulbecco’s phosphate-buffered saline [PBS], Corning, NY) following the previously described methods (Kechad et al., 2012), and neuronal suspension was plated on acid-washed glass coverslips pre-coated with poly-D-lysine (Trevigen, 100 μg/ml) for 1 hr and laminin (Trevigen, 5 μg/ml) overnight at 37°C. Culture medium was made up of half DMEM/F12 medium (Gibco) and half neurobasal medium (Gibco), supplemented with B27 supplement (Life, 0.5×), penicillin-streptomycin (Life, 1×), N-2 supplement (Gibco, 0.5×), N-acetyl-L-cysteine (Sigma, NAC 0.6 mg/ml), cpt-cAMP (Sigma, 100 μM), forskolin (Sigma, 10 μM), and insulin (Sigma, 25 μg/ml). EGF (PeproTech, 50 ng/ml), BDNF (PeproTech, 50 ng/ml), NT-3 (PeproTech, 25 ng/ml), and FGF-basic (PeproTech, 10 ng/ml) were freshly added before using.

KD using lentiviral shRNA, siRNA or AAV shRNA, and overexpression using AAV system

Request a detailed protocol

Lentiviral KD plasmids encoding shRNA (shCtrl: 5’-GCATCAAGGTGAACTTCAAGA-3’; shYthdf2: 5’-GGACGTTCCCAATAGCCAACT-3’; shYthdf1: 5’- GGACATTGGTACTTGGGATAA-3’; shYthdf3: 5’- GGATTTGGCAATGATACTTTG-3’; shMettl14#6: 5’-GCTGGACCTGGGATGATATTA-3’; shMettl14#7: 5’-CCCAGCTTGTACTTTGCTTTA-3’) were generated from pLKO.1-TRC and lentivirus preparation process was described previously (Yu et al., 2018). All siRNAs were chosen from previous studies and the target sequences of siRNA are as following: siCtrl (RNAi negative control): 5’- UUCUCCGAACGUGUCACGUTT-3’ (Yu et al., 2018); siKalrn7: 5’- AGUACAAUCCUGGCCAUGUTT-3’ (Xie et al., 2007); siKalrn9: 5’-ACUGGACUGGACUUCUAUUTT-3’ (Yan et al., 2015); siKalrn12: 5’-CGAUGAGCUGAUGGAAGAATT-3’ (Yan et al., 2015); siStrn: 5’-GGUGAAGAUCGAGAUACAATT-3’ (Breitman et al., 2008); siUbr4: 5’-AAUGAUGAGCAGUCAUCUATT-3’ (Shim et al., 2008). AAV KD plasmids encoding shRNA (shCtrl: 5’-TTCTCCGAACGTGTCACGTAA-3’; shKalrn12: 5’-TGATGAGCTGATGGAAGAA-3’; shUbr4: 5’-AATGATGAGCAGTCATCTC-3’) were generated using pHBAAV-U6-MCS-CMV-EGFP and packaged in serotype-9 by Hanbio (1.5 × 1012 genomic copies per ml). AAV overexpression plasmids of Hspa12a (NM_175199.3; PCR primer for mouse Hspa12a: 5’-ATGGCGGACAAGGAAGCTGG-3’ and 5’-GTAATTTAAGAAGTCGATCCCC-3’) and Islr2 (NM_001161541.1; PCR Primer for mouse Islr2: 5’-ATGGGGCCCTTTGGAGC-3’ and 5’-GCCCGCTGTCTGCCTGTAG-3’) were generated from pHBAAV-CMV-MCS-3flag-T2A-ZsGreen and packaged serotype-9 by Hanbio (1.2 × 1012 genomic copies per ml).

GeneSilencer Transfection Reagent (Genlantis) was used in siRNA transfection following the manufacturer’s protocols. Culture medium was changed after 1 day of lentiviral shRNA infection or siRNA transfection. For lentiviral shRNA assay, puromycin (Thermo or Sigma, 1 μg/ml) was added after 2 days of infection. Immunofluorescence, RNA, or protein preparation was performed after shRNA or siRNA worked for 3 days. For AAV intravitreal injection, P0-P1 mouse pups were anesthetized in ice and then eyes were pierced at the edge of corneal by 30G × 1/2 needle (BD, 305106) under stereomicroscope. Then 1 μl AAV was intravitreally injected with 10 µl Syringe (Hamilton, 80330) following the pinhole. P15 or adult mice were anesthetized with 2.5% Avertin and then eyes were pierced at the side of corneal and the outer segment of sclera by 30G × 1/2 needle successively. Two μl AAV was intravitreally injected with 10 µl Syringe following the pinhole on the sclera. All subsequent experiments such as AOH operation and immunostaining were carried out after at least 3 weeks (10 days for ZsGreen/CART labeling of ooDSGCs in Ythdf2 cKO and control mice in Figure 3A).

RT-qPCR

Request a detailed protocol

Total RNA was extracted from cells or tissues with TRIzol Reagent (Life) and then used for reverse transcription by PrimeScript RT Master Mix (TaKaRa). Synthesized cDNA was used for qPCR by 2× ChamQ Universal SYBR qPCR Master Mix (Vazyme) on StepOnePlus Real-Time PCR System (ABI) or BioRad CFX96 Touch Real-Time PCR system. Primers used for qPCR are as following: mouse Gapdh: 5’-TTGTCAGCAATGCATCCTGCACCACC-3’ and 5’-CTGAGTGGCAGTGATGGCATGGAC-3’ (Mains et al., 2011); mouse Kalrn7: 5’- GATACCATATCCATTGCCTCCAGGACC-3’ and 5’-CCAGGCTGCGCGCTAAACGTAAG-3’ (Mains et al., 2011); mouse Kalrn9: 5’- GCCCCTCGCCAAAGCCACAGC-3’ and 5’-CCAGTGAGTCCCGTGGTGGGC-3’ (Mains et al., 2011); mouse Kalrn12: 5’- CAGCAGCCACGTGCCTGCAGC-3’ and 5’-TCTTGACATTGGGAATGGGCCGCAC-3’ (Mains et al., 2011); mouse Strn: 5’-TGAAGCCTGGAATGTGGACC-3’ and 5’-CTATTGGGCCTCTTCACCCC-3’; mouse Ubr4: 5’- TGAGTGAGGACAAGGGCAAC-3’ and 5’-GGGTTGGATCGAACGAAGGT-3’; mouse Ythdf2: 5’-GAGCAGAGACCAAAAGGTCAAG-3’and 5’-CTGTGGGCTCAAGTAAGGTTC-3’; 18 s: 5’-GCTTAATTTGACTCAACACGGGA-3’ and 5’-AGCTATCAATCTGTCAATCCTGTC-3’ (Wang et al., 2018); mouse Hspa12a: 5’-GGGTTTGCACAGGCTAAGGA-3’ and 5’-TCTGATGGACGGTCAGGTCT-3’; mouse Islr2: 5’-GAAGCTCCCTTAGACTGTCACC-3’ and 5’-CCCCATCGTGACTCCTGCTG-3’.

Immunofluorescence and immunostaining

Request a detailed protocol

For tissue sections, mouse embryonic eyes were fixed with 4% PFA (Sigma) in 0.1 M phosphate buffer (PB) for 30–45 min at room temperature (RT); eyes of mouse pups (<P10) were pre-fixed briefly and then eyecups were dissected and fixed for 45 min-1 hr at RT; for P20-30 or adult mice, eyecups were dissected after myocardial perfusion with 0.9% NaCl, followed by fixation for 1 hr. After PBS (3 × 5 min) washing, tissues were dehydrated with 30% sucrose in 0.1 M PB overnight at 4°C, then embedded with OCT (SAKURA) and cryosectioned at 12 μm (20 μm for Thy1-GFP section analysis) with Leica CM1950 Cryostat. Tissue sections were permeabilized and blocked with 10% ChemiBLOCKER (Millipore) and 0.5% Triton X-100 (Sigma) in PBS (PBST) for 1 hr at RT and incubated in PBST overnight at 4°C with following primary antibodies: chicken anti-GFP (1:1000, Abcam ab13970), chicken anti-MAP2 (1:10,000, Abcam ab5392), goat anti-VAChT (1:1000, Millipore ABN100), guinea pig anti-RBPMS (1:1000, PhosphoSolutions 1832-RBPMS), mouse anti-AP2α (1:1000, DSHB 3B5), mouse anti-Bassoon (1:2500, Enzo Life Sciences ADI-VAM-PS003), mouse anti-Brn3a (1:300, Millipore MAB1585), mouse anti-Calbindin-D-28K (1:200, Sigma C9848), mouse anti-PKCα (1:500, Santa Cruz sc-8393), rabbit anti-Strn (Striatin) (1:500, BD Biosciences 610838), rabbit anti-CART (1:2000, Phoenix Pharmaceuticals H-003–62), rabbit anti-m6A (1:200, Synaptic Systems 202003), rabbit anti-melanopsin (1:1000, Thermo PA1-780), rabbit anti-PKCα (1:1000, Cell Signaling CST-2056), rabbit anti-PSD95 (1:1000, Abcam ab18258), rabbit anti-Recoverin (1:1000, Millipore AB5585), rabbit anti-YTHDF2 (1:1000, Proteintech 24744–1-AP), rabbit anti-YTHDF1 (1:1000, Proteintech 17479–1-AP), rabbit anti-YTHDF3 (1:1000, Abcam ab103328), rabbit anti-Ubr4 (1:300, Abcam ab86738), sheep anti-Chx10 (1:1000, Exalpha X1179P), chicken anti-GFAP (1:500, Millipore AB5541), goat anti-Lhx2 (1:200, Santa Cruz Biotechnology sc-19344), rabbit anti-Lhx2 (1:500, Abcam ab184337). After three times of PBS washing, sections were incubated in PBST for 1 hr at RT with secondary antibodies: Alexa 488 donkey anti-chicken (1:500, Jackson 703-545-155), Alexa 488 donkey anti-guinea pig (1:500, Jackson 706-545-148), Alexa 488 donkey anti-mouse (1:500, Thermo A21202), Alexa 488 donkey anti-rabbit (1:500, Thermo A21206), Alexa 555 donkey anti-goat (1:1000, Thermo A21432), Alexa 555 donkey anti-mouse (1:1000, Thermo A31570), Alexa 555 donkey anti-rabbit (1:1000, Thermo A31572), Alexa 555 donkey anti-sheep (1:1000, Thermo A21436), Alexa 555 goat anti-chicken (1:1000, Thermo A21437), or Alexa 647 donkey anti-mouse (1:200, Thermo A31571) and then mounted with the VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratory).

For cultured neurons, after twice of PBS washing, cells were fixed for 15 min with 4% PFA in 0.1 M PB at RT, then washed with PBS three times and blocked in PBST for 20 min at RT. Antibody incubation conditions are the same as tissue sections.

For wholemount immunostaining of retina, eyes were dissected after myocardial perfusion with 0.9% NaCl. Then retinas were separated from sclera and fixed with 4% PFA in 0.1 M PB for 1 hr at RT. Then retinas were blocked with 5% normal goat serum (Novus), 0.4% Triton X-100 in PBS overnight at 4°C. Primary antibodies such as chicken anti-GFP (1:1000, Abcam ab13970), mouse anti-Brn3a (1:300, Millipore MAB1585), mouse anti-SMI-32 (1:200, BioLegend 801701), or rabbit anti-Melanopsin (1:1000, Thermo PA1-780), rabbit anti-CART (1:2000, Phoenix Pharmaceuticals H-003–62) were diluted in 5% normal goat serum, 0.4% Triton X-100 in PBS and incubated overnight at 4°C. Then retinas were incubated with Alexa 488 donkey anti-chicken (1:500, Jackson 703-545-155), Alexa 488 donkey anti-mouse (1:500, Thermo A21202), Alexa 555 donkey anti-mouse (1:1000, Thermo A-31570) and Alexa 555 donkey anti-rabbit (1:1000, Thermo A31572) secondary antibodies in 5% normal goat serum (Novus), 0.4% Triton X-100 in PBS and finally mounted with the VECTASHIELD Antifade Mounting Medium with DAPI.

All images were captured on Nikon A1R confocal microscope or Zeiss LSM 800 confocal microscope with identical settings for each group in the same experiment. A region of interest, length or thickness in immunofluorescence experiments were obtained with ImageJ. The number of neurons in specific area was counted blindly and manually. To quantify RGC dendrite lamination in IPL with Thy1-GFP, z-stack and maximum projection were performed during the analysis. GFP intensity values across IPL depth were measured by ImageJ/Analyze/Plot Profile function (Liu et al., 2018). To quantify the numbers of Bassoon+/PSD-95+ excitatory synapses in IPL, the colocalization puncta was measured by ImageJ/Analyze/Puncta Analyzer as described previously (Ippolito and Eroglu, 2010).

Sholl analysis

Request a detailed protocol

For confocal images of cultured RGCs, MAP2 signals in original format were analyzed with simple neurite tracer and then quantified with Sholl analysis (5 μm per distance from soma center) which was a widely used method in neurobiology to quantify the complexity of dendritic arbors using ImageJ (Schindelin et al., 2012; Binley et al., 2014). Retina wholemount data were captured in z-stack mode (0.5–1 μm per slide) with confocal microscopes. ZsGreen, eGFP, and SMI-32 signals were directly analyzed with simple neurite tracer and then z projection of all tracers was quantified with Sholl analysis (10 μm per distance from soma center), while melanopsin signals were maximum-projected before tracing.

OMR assay

Request a detailed protocol

Ythdf2 cKO and control mice aged about 6 weeks were dark-adapted overnight before experiment and used in the OMR assay following the previously reported protocols (Douglas et al., 2005; Sergeeva et al., 2018). Using the Matlab program, 0.2 c/deg (15 s per direction of rotation) was first used for mice to adapt this experiment, and 0.3, 0.35, 0.4, 0.43, 0.45, 0.47, 0.5 and 0.55 c/deg (30 s per direction of rotation) were used in the following recordings. Mouse behaviors were analyzed in real time during the experiment and re-checked with video recordings. Finally, data for each mouse were determined by the minimal spatial frequency between left and right OMR.

CTB labeling of optic nerve

Request a detailed protocol

To label RGC axon terminals in mouse brain, RGC axons were anterogradely labeled by CTB conjugated with Alexa Fluor 555 (Invitrogen, C34776) through intravitreal injection 48 hr before sacrifice. After PFA perfusion, the brains were fixed with 4% PFA in 0.1 M PB overnight, dehydrated with 15% sucrose and 30% sucrose in 0.1 M PB overnight at 4°C sequentially, embedded with OCT for coronal section, and cryosectioned at 12 μm with Leica CM1950 Cryostat. After PBS washing, the sections were mounted with VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratory). The images were captured on Tissue Genostics with identical settings for each group in the same experiment with the TissueFAXS 7.0 software.

RIP and sequencing

Request a detailed protocol

For RIP experiment, we used the EZ-Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore) following the manual with minor modifications. Briefly, 1 × 107 retinal neurons were subjected to each 100 μl lysis buffer. The amount of YTHDF2 antibody (Proteintech, 24744–1-AP) and control IgG used for immunoprecipitation is 5 μg, respectively. RIP experimental steps, RNA sample preparation and sequencing, and sequence data analysis followed the procedures reported previously (Yu et al., 2021a).

MS analysis

Request a detailed protocol

E15.5 retinal neurons were cultured and infected with lentiviral shYthdf2 or shCtrl. Sample collection and lysis, protein and peptide preparation were performed following procedures reported previously (Yu et al., 2021b). Proteins with fold changes greater than 1.3 and p values less than 0.05 were considered to be regulated by YTHDF2 KD with statistical significance.

Anti-m6A immunoprecipitation

Request a detailed protocol

Total retinal RNA was extracted from P0 WT mouse pups. Immunoprecipitation of m6A-modified transcripts was carried out with Magna MeRIP m6A Kit (Merck-Millipore, 17–10499) following the manual. m6A antibody (Synaptic Systems, 202003) and corresponding control IgG were used in this experiment. The RNA samples pulled down from the experiment were used for RT-qPCR.

AOH model

Request a detailed protocol

Mice were anesthetized with 5% chloral hydrate in normal saline (10 μl/g) based on body weight and the Compound Tropicamide Eye Drops were used to scatter pupil. The anterior chamber was penetrated using the 32G × 1/2’’ needles (TSK) and filled with the BBS Sterile Irrigating Solution (Alcon) which was hung at a high position to provide proper pressure. Intraocular pressure was measured with the Tonolab tonometer (icare) for every 10 min and maintained at 85–90 mmHg for 1 hr. Levofloxacin hydrochloride was used after the operation and mice were revived in a 37°C environment. Retinas were analyzed for gene expression of YTHDF2 1 day after AOH, gene expression of Hspa12a and Islr2 3 days after AOH, dendritic complexity and RGC number 3–7 days after AOH.

Statistical analysis

Request a detailed protocol

All experiments were conducted at a minimum of three independent biological replicates (two biological replicates for the RIP assay) or three mice/pups for each genotype/condition in the lab. Data are mean ± SEM. Statistical analysis was preformed using GraphPad Prism 7.0. When comparing the means of two groups, an unpaired or paired t test was performed on the basis of experimental design. The settings for all box and whisker plots are: 25th-75th percentiles (boxes), minimum and maximum (whiskers), and medians (horizontal lines). A p value less than 0.05 was considered as statistically significant: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Data availability

The RIP-seq data have been deposited to the Gene Expression Omnibus (GEO) with accession number GSE145390. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD017775.

The following data sets were generated
    1. Niu F
    2. Yang L
    3. Ji S
    (2022) NCBI Gene Expression Omnibus
    ID GSE145390. Anti YTHDF2 RIP-seq to identify YTHDF2 target mRNAs in P0 mouse retinas.
    1. Niu F
    2. Ji S
    (2022) PRIDE
    ID PXD017775. Proteome analysis using mass spectrometry (MS) in acute shYthdf2-mediated knockdown of cultured RGCs.

References

    1. Agudo M
    2. Pérez-Marín MC
    3. Lönngren U
    4. Sobrado P
    5. Conesa A
    6. Cánovas I
    7. Salinas-Navarro M
    8. Miralles-Imperial J
    9. Hallböök F
    10. Vidal-Sanz M
    (2008)
    Time course profiling of the retinal transcriptome after optic nerve transection and optic nerve crush
    Molecular Vision 14:1050–1063.
    1. Weber AJ
    2. Kaufman PL
    3. Hubbard WC
    (1998)
    Morphology of single ganglion cells in the glaucomatous primate retina
    Investigative Ophthalmology & Visual Science 39:2304–2320.

Article and author information

Author details

  1. Fugui Niu

    1. School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    2. SUSTech-HIT Joint Graduate Program, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing
    Competing interests
    No competing interests declared
  2. Peng Han

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization
    Competing interests
    No competing interests declared
  3. Jian Zhang

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared
  4. Yuanchu She

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared
  5. Lixin Yang

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared
  6. Jun Yu

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared
  7. Mengru Zhuang

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared
  8. Kezhen Tang

    Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared
  9. Yuwei Shi

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Investigation
    Competing interests
    No competing interests declared
  10. Baisheng Yang

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Investigation
    Competing interests
    No competing interests declared
  11. Chunqiao Liu

    State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
    Contribution
    Investigation, Resources
    Competing interests
    No competing interests declared
  12. Bo Peng

    1. Department of Neurosurgery, Jinshan Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China
    2. Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, China
    Contribution
    Conceptualization, Methodology, Resources, Software, Supervision, Writing – review and editing
    For correspondence
    peng@fudan.edu.cn
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4183-5939
  13. Sheng-J Ji

    School of Life Sciences, Department of Biology, Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Brain Research Center, Southern University of Science and Technology, Shenzhen, China
    Contribution
    Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing
    For correspondence
    jisj@sustech.edu.cn
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3380-258X

Funding

National Natural Science Foundation of China (31871038)

  • Sheng-J Ji

National Natural Science Foundation of China (31922027)

  • Bo Peng

Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions (2021SHIBS0002)

  • Sheng-J Ji

High-Level University Construction Fund for Department of Biology (G02226301)

  • Sheng-J Ji

Science and Technology Innovation Commission of Shenzhen Municipality (ZDSYS20200811144002008)

  • Sheng-J Ji

Program of Shanghai Subject Chief Scientist (21XD1420400)

  • Bo Peng

Innovative Research Team of High-Level Local University in Shanghai

  • Bo Peng

Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions (2019SHIBS0002)

  • Sheng-J Ji

National Natural Science Foundation of China (32170955)

  • Sheng-J Ji

National Natural Science Foundation of China (32170958)

  • Bo Peng

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Ke Wang and Kwok-Fai So (Jinan University) for help on the OMR assay. We thank Mengqing Xiang and Suo Qiu (Zhongshan Ophthalmic Center, Sun Yat-sen University) for help on AAV experiments. We thank other members of Ji laboratory for technical support, helpful discussions, and comments on the manuscript. This work was supported by National Natural Science Foundation of China (31871038 and 32170955 to S-JJ; 31922027 and 32170958 to BP), Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions (2021SHIBS0002, 2019SHIBS0002), High-Level University Construction Fund for Department of Biology (internal grant no. G02226301), Science and Technology Innovation Commission of Shenzhen Municipal Government (ZDSYS20200811144002008), Program of Shanghai Subject Chief Scientist (21XD1420400), and the Innovative Research Team of High-Level Local University in Shanghai (BP).

Ethics

All experiments using mice were carried out following the animal protocols approved by the Laboratory Animal Welfare and Ethics Committee of Southern University of Science and Technology (approval numbers: SUSTC-JY2017004, SUSTC-JY2019081).

Version history

  1. Received: November 24, 2021
  2. Preprint posted: December 7, 2021 (view preprint)
  3. Accepted: February 16, 2022
  4. Accepted Manuscript published: February 18, 2022 (version 1)
  5. Version of Record published: March 9, 2022 (version 2)
  6. Version of Record updated: March 14, 2022 (version 3)
  7. Version of Record updated: April 4, 2022 (version 4)

Copyright

© 2022, Niu et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,735
    Page views
  • 371
    Downloads
  • 17
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Fugui Niu
  2. Peng Han
  3. Jian Zhang
  4. Yuanchu She
  5. Lixin Yang
  6. Jun Yu
  7. Mengru Zhuang
  8. Kezhen Tang
  9. Yuwei Shi
  10. Baisheng Yang
  11. Chunqiao Liu
  12. Bo Peng
  13. Sheng-J Ji
(2022)
The m6A reader YTHDF2 is a negative regulator for dendrite development and maintenance of retinal ganglion cells
eLife 11:e75827.
https://doi.org/10.7554/eLife.75827

Share this article

https://doi.org/10.7554/eLife.75827

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.